Dr Reddys Laboratories Ltd vs Piramal Pharma Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 03, 2026

Key Highlights

The Latest Trading Price of Dr Reddys Laboratories Ltd is ₹ 1322 as of 30 Apr 15:30 . The P/E Ratio of Dr Reddys Laboratories Ltd changed from 38.5 on March 2021 to 16.9 on March 2025 . This represents a CAGR of -15.18% over 5 yearsThe P/E Ratio of Piramal Pharma Ltd changed from 991.5 on March 2024 to 325.4 on March 2025 . This represents a CAGR of -42.71% over 2 years The Market Cap of Dr Reddys Laboratories Ltd changed from ₹ 75095 crore on March 2021 to ₹ 95465 crore on March 2025 . This represents a CAGR of 4.92% over 5 yearsThe Market Cap of Piramal Pharma Ltd changed from ₹ 8165 crore on March 2023 to ₹ 29763 crore on March 2025 . This represents a CAGR of 53.90% over 3 years The revenue of Dr Reddys Laboratories Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 9024 crore. This represent the decline of -100% The revenue of Piramal Pharma Ltd for the Mar '26 is ₹ 2811 crore as compare to the Dec '25 revenue of ₹ 2193 crore. This represent the growth of 28.18% The ebitda of Dr Reddys Laboratories Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 2158 crore. This represent the decline of -100% The ebitda of Piramal Pharma Ltd for the Mar '26 is ₹ 344.37 crore as compare to the Dec '25 ebitda of ₹ 208.12 crore. This represent the growth of 65.47% The net profit of Dr Reddys Laboratories Ltd changed from ₹ 1392 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% The net profit of Piramal Pharma Ltd changed from ₹ -88.64 crore to ₹ -8.83 crore over 8 quarters. This represents a CAGR of -68.44% The Dividend Payout of Dr Reddys Laboratories Ltd changed from 19.03 % on March 2021 to 12.47 % on March 2025 . This represents a CAGR of -8.11% over 5 yearsThe Dividend Payout of Piramal Pharma Ltd changed from 18.07 % on March 2022 to 2.68 % on March 2025 . This represents a CAGR of -37.94% over 4 years .

About Dr Reddys Laboratories Ltd

Dr Reddy's Laboratories Limited (DRL) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives.
Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products - Dr. Reddy's portfolio of products and services include Active Pharmaceutical Ingredients (APIs), custom pharmaceutical services, generics, biosimilars and differentiated formulations.
The company's major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.
Dr. Reddy's operates in markets across the globe.
Its major markets include - USA, India, Russia & CIS countries, and Europe. Dr Reddy's Laboratories Limited was incorporated in 1984 in Hyderabad.

About Piramal Pharma Ltd

Piramal Pharma Limited was incorporated on March 4, 2020 as a Public Limited Company and registered with the RoC. The Company offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 17 global facilities and a global distribution network in over 100 countries.
It includes an integrated CDMO business, CHG business and ICH business, selling over-the-counter products in India.
In addition, it has a joint venture with Allergan, a leader in ophthalmology in the Indian formulations market. PPL is a leading pharmaceutical company with global operations, providing end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and global distribution network.
It operate under three business verticals - Piramal Pharma Solutions, an integrated contract development and manufacturing organization (CDMO) having a product suite in niche areas such as highly potent Active pharmaceutical ingredients (APIs), Finished dosage forms (FDFs), antibody drug conjugates, potent sterile injectable, hormonal oral solid dosage forms, biologics and vaccines; Piramal Critical Care, a complex hospital generics (CHG) business in the areas of inhalation anaesthesia, injectable anaesthesia and pain management, intrathecal therapy and other injectable; and India consumer healthcare (ICH) business, selling well-known OTC brands.

FAQs for the comparison of Dr Reddys Laboratories Ltd and Piramal Pharma Ltd

Which company has a larger market capitalization, Dr Reddys Laboratories Ltd or Piramal Pharma Ltd?

Market cap of Dr Reddys Laboratories Ltd is 110,420 Cr while Market cap of Piramal Pharma Ltd is 21,520 Cr

What are the key factors driving the stock performance of Dr Reddys Laboratories Ltd and Piramal Pharma Ltd?

The stock performance of Dr Reddys Laboratories Ltd and Piramal Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Dr Reddys Laboratories Ltd and Piramal Pharma Ltd?

As of May 3, 2026, the Dr Reddys Laboratories Ltd stock price is INR ₹1322.95. On the other hand, Piramal Pharma Ltd stock price is INR ₹161.9.

How do dividend payouts of Dr Reddys Laboratories Ltd and Piramal Pharma Ltd compare?

To compare the dividend payouts of Dr Reddys Laboratories Ltd and Piramal Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.